- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02561923
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
June 12, 2017 updated by: Janssen Scientific Affairs, LLC
Randomized, Parallel-Group, 2-Part Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding Parameters and Pharmacodynamics After a Punch Biopsy Procedure in Healthy Subjects Treated With Rivaroxaban
The purpose of this study is to assess the independent effects of both a 4-Factor prothrombin complex concentrate (PCC) - (Kcentra) and Tranexamic acid (TXA) on the bleeding parameters (bleeding duration and blood volume) following a punch biopsy, in addition to assessing their effects on the anticoagulant/pharmacodynamic (prothrombin time and endogenous thrombin potential) changes induced by rivaroxaban at steady state, to better understand their potential role in bleeding reversal.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a 2 part, single center study to be conducted in healthy men and women.
Part 1 (open-label) consists of Screening Phase (within 28 days before admission into the study center on Day -1), followed by a 3 day treatment period and a follow-up visit on Day 8.
A single oral 20 milligram (mg) dose of rivaroxaban will be administered on Day 1. Pharmacokinetic (PK), pharmacodynamics (PD), and punch biopsy parameters will be assessed.
Part 2 (double-blind) consists of Screening Phase (within 28 days before admission into the study center on Day -1), followed by a 8 day treatment period (Day -1 to Day 7) and a follow-up visit on Day 11.
Rivaroxaban (20 mg every 12 hrs) will be administered on Days 1 through 3 and single 20 mg dose will be given on the morning of Day 4. A single dose of either 4-factor PCC, TXA or saline (Placebo) will be administered in a randomized, blinded fashion on Day 4. PK, PD, Exploratory Bio-markers and punch biopsy parameters will be assessed.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
158
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body mass index (weight kilogram [kg]/height^2 meters [m]^2) between 18 and 30 kg/m2 (inclusive), and body weight between 50 and 100 kg;
- Participants must have coagulation test results of prothrombin time (PT) and a partial thromboplastin time (PTT) within normal limits at Screening
- Must have normal renal function, as per medical history
- If a woman, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (eg, double-barrier method or male partner sterilization) before entry and throughout the study. (Note: combined hormonal contraception should not be used)
- Non-smoker (Note: subjects should not have used nicotine-containing products within 30 days before study drug administration)
- If a woman, must have a negative serum Beta-human chorionic gonadotropin (hCG)] pregnancy test at Screening; and a negative serum pregnancy test on Day -1 of the study
- If a man, must agree to use adequate contraception method as deemed appropriate by the investigator (eg, vasectomy, double-barrier, partner using effective contraception) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug
Exclusion Criteria:
- History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease (including history of definite myocardial infarction, cerebrovascular accident, percutaneous transluminal coronary angioplasty or coronary artery bypass graft within 6 months before the Screening visit, or a previous intracranial hemorrhage at any time, known history of lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, seizure disorder, infection, skin disease, or any other illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results
- Participants with any history of thrombosis, inherited or acquired thrombophilia, bleeding diathesis or coagulopathy (including any abnormal bleeding or blood dyscrasias), hematologic disease, clinically significant hemorrhagic disorder, excessive bruising, bleeding from nose or gums or known disorders with increased bleeding risk (eg, acute gastritis, acute peptic ulcer), serious bleeding including gastrointestinal bleeding requiring hospitalization, intracranial bleeding of any type, or uncontrollable postoperative bleeding
- Known antithrombin III, Protein C, or Protein S deficiency, Factor V Leiden or prothrombin gene 20210 mutation, anticardiolipin (immunoglobulin G [IgG] and immunoglobulin M [IgM]) or antiphospholipid antibodies, or family history of unexplained thrombotic disorders
- History of intracranial tumor or aneurysm or known abdominal aneurysm
- Clinically significant abnormal physical examination, vital signs or 12-lead electrocardigram [ECG] at Screening or at admission to the study center on Day -1, as deemed appropriate by the investigator. This would include: resting pulse >100 or <40 beats per min, blood pressure systolic >140 or <90 millimeters per mercuric level [mmHg], and diastolic blood pressure > 90 or < 50 mmHg (pulse and blood pressure measurements should be taken in a supine position, after resting for at least 5 minutes)
- Participants for whom surface blood vessels could not be visualized, or who have a history of likelihood of forming keloid scars
- Use of any prescription or nonprescription medication (including antiplatelet, anticoagulants, aspirin, non-steroidal anti-inflammatory drugs, vitamins and herbal supplements), within 7 days before the first dose of the study drug is scheduled
- Known allergy to the study drugs or any of the excipients of the formulations
- Unable to swallow solid, oral dosage forms whole with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rivaroxaban
Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
|
A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
|
Experimental: Rivaroxaban plus tranexamic acid (TXA)
Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally.
Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
|
A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
|
Experimental: Rivaroxaban plus Kcentra
Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally.
Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 [international units per minute] IU/min) on Day 4 in Part 2.
|
A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 [international units] IU/min) on Day 4.
|
Experimental: Rivaroxaban plus Saline
Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally.
Following rivaroxaban adminsitration on Day 4, saline [Kcentra saline control or TXA saline control] on Day 4 in Part 2.
|
A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
Saline [Kcentra saline control or TXA saline control] on Day 4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Blood Volume in Part 1
Time Frame: Day-1 (Baseline) and 4 hour (hr) postdose on Day 1
|
Volume of blood (BV) collected after a punch biopsy is performed.
|
Day-1 (Baseline) and 4 hour (hr) postdose on Day 1
|
Change From Baseline in Bleeding Duration in Part 1
Time Frame: Day-1 (Baseline) and 4 hr postdose on Day 1
|
Bleeding duration (BD) after a punch biopsy is performed.
|
Day-1 (Baseline) and 4 hr postdose on Day 1
|
Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Lag-time in Part 2
Time Frame: Predose (Baseline) and up to 72 hrs postdose on Day 4
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in lag time (time required until thrombin is generated) will be observed.
|
Predose (Baseline) and up to 72 hrs postdose on Day 4
|
Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Peak in Part 2
Time Frame: Predose (Baseline) and 72 hours postdose on Day 4
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in peak (the maximal effect on thrombin generation) will be observed.
|
Predose (Baseline) and 72 hours postdose on Day 4
|
Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Time to Peak in Part 2
Time Frame: Predose (Baseline) and 72 hours postdose on Day 4
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in time-to-peak (time required to reach maximal effect on thrombin generation) will be observed.
|
Predose (Baseline) and 72 hours postdose on Day 4
|
Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 2
Time Frame: Predose (Baseline) up to 72 hours on Day 4
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in AUC (the overall effect on thrombin generation) will be observed.
|
Predose (Baseline) up to 72 hours on Day 4
|
Mean Change in Prothrombin Time (PT) in Part 2
Time Frame: Predose (Baseline) up to 72 hours on Day 4
|
Prothrombin Time is a global clotting test that is used for the assessment of the extrinsic pathway of the blood coagulation cascade.
|
Predose (Baseline) up to 72 hours on Day 4
|
Change From Baseline in Blood Volume in Part 2
Time Frame: Predose (Baseline) and 72 hours on Day 4
|
Predose (Baseline) and 72 hours on Day 4
|
|
Change From Baseline in Bleeding Duration in Part 2
Time Frame: Predose (Baseline) and 72 hours on Day 4
|
Predose (Baseline) and 72 hours on Day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) in Part 1
Time Frame: Predose and up to 24 hrs postdose on Day 1
|
Predose and up to 24 hrs postdose on Day 1
|
|
Time to Maximum Observed Plasma Concentration in Part 1 (Tmax)
Time Frame: Predose and up to 24 hrs post-dose
|
Predose and up to 24 hrs post-dose
|
|
Area under Plasma Concentration Time Curve From Time 0 to 24 in Part 1 (AUC [0 TO 24]
Time Frame: Predose and up to 24 hrs postdose on Day 1
|
Predose and up to 24 hrs postdose on Day 1
|
|
Maximum Observed Plasma Concentration (Cmax) in Part 2
Time Frame: Predose and up to 72 hrs postdose on Day 4
|
Predose and up to 72 hrs postdose on Day 4
|
|
Minimum Observed Plasma Concentration (Cmin) in Part 2
Time Frame: Predose Days 1 to 4
|
Predose Days 1 to 4
|
|
Time to Maximum Observed Plasma Concentration (Tmax) in Part 2
Time Frame: Predose and up to 72 hrs postdose on Day 4
|
Predose and up to 72 hrs postdose on Day 4
|
|
Area under plasma concentration time curve during the dosing interval (AUCtau) in Part 2
Time Frame: Predose and up to 24 hours
|
Predose and up to 24 hours
|
|
Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Lag-time in Part 1
Time Frame: Predose (Baseline) up to 24 hours on Day 1
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in lag time (time required until thrombin is generated) will be observed.
|
Predose (Baseline) up to 24 hours on Day 1
|
Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Peak in Part 1
Time Frame: Predose (Baseline) up to 24 hours on Day 1
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in peak (the maximal effect on thrombin generation) will be observed.
|
Predose (Baseline) up to 24 hours on Day 1
|
Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Time to Peak in Part 1
Time Frame: Predose (Baseline) up to 24 hours on Day 1
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in time-to-peak (time required to reach maximal effect on thrombin generation) will be observed.
|
Predose (Baseline) up to 24 hours on Day 1
|
Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 1
Time Frame: Predose (Baseline) up to 24 hours on Day 1
|
The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.
The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade.
Change in AUC (the overall effect on thrombin generation) will be observed.
|
Predose (Baseline) up to 24 hours on Day 1
|
Mean Change in Prothrombin Time (PT) in Part 1
Time Frame: Predose (Baseline) up to 24 hours on Day 1
|
Prothrombin Time is a global clotting test that is used for the assessment of the extrinsic pathway of the blood coagulation cascade.
|
Predose (Baseline) up to 24 hours on Day 1
|
Trough Plasma Concentration (Ctrough) in Part 2
Time Frame: Predose and up to 72 hrs postdose on Day 4
|
Ctrough is the trough plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose.
|
Predose and up to 72 hrs postdose on Day 4
|
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time Frame: Up to 37 Days (Part 1) and Up to 40 Days (Part 2)
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Up to 37 Days (Part 1) and Up to 40 Days (Part 2)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 27, 2015
Primary Completion (Actual)
June 17, 2016
Study Completion (Actual)
June 17, 2016
Study Registration Dates
First Submitted
August 21, 2015
First Submitted That Met QC Criteria
September 25, 2015
First Posted (Estimate)
September 28, 2015
Study Record Updates
Last Update Posted (Actual)
June 14, 2017
Last Update Submitted That Met QC Criteria
June 12, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR107832
- 39039039NAP1004 (Other Identifier: Janssen Scientific Affairs, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Rivaroxaban
-
Portola PharmaceuticalsCompleted
-
Korea University Anam HospitalRecruitingAtrial Fibrillation | Anticoagulant Adverse ReactionKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
China National Center for Cardiovascular DiseasesNot yet recruitingStroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
-
BayerCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
BayerJanssen R&D, L.L.C.Completed
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
University Hospital, GrenobleCompleted
-
Addpharma Inc.CompletedEmbolism and ThrombosisKorea, Republic of